These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 22489659)

  • 21. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer.
    DeGrado TR; Coleman RE; Wang S; Baldwin SW; Orr MD; Robertson CN; Polascik TJ; Price DT
    Cancer Res; 2001 Jan; 61(1):110-7. PubMed ID: 11196147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of [(11)C]Choline ([(11)C]CHO) and [(18)F]Bombesin (BAY 86-4367) as Imaging Probes for Prostate Cancer in a PC-3 Prostate Cancer Xenograft Model.
    Schwarzenböck SM; Schmeja P; Kurth J; Souvatzoglou M; Nawroth R; Treiber U; Kundt G; Berndt S; Graham K; Senekowitsch-Schmidtke R; Schwaiger M; Ziegler SI; Dinkelborg L; Wester HJ; Krause BJ
    Mol Imaging Biol; 2016 Jun; 18(3):393-401. PubMed ID: 26483088
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical Evaluation and Pilot Clinical Study of Al
    Liu T; Liu C; Xu X; Liu F; Guo X; Li N; Wang X; Yang J; Yang X; Zhu H; Yang Z
    J Nucl Med; 2019 Sep; 60(9):1284-1292. PubMed ID: 30796170
    [TBL] [Abstract][Full Text] [Related]  

  • 24. One-Step
    Kuo HT; Lepage ML; Lin KS; Pan J; Zhang Z; Liu Z; Pryyma A; Zhang C; Merkens H; Roxin A; Perrin DM; Bénard F
    J Nucl Med; 2019 Aug; 60(8):1160-1166. PubMed ID: 30737299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MicroPET imaging of prostate cancer in LNCAP-SR39TK-GFP mouse xenografts.
    Yang H; Berger F; Tran C; Gambhir SS; Sawyers CL
    Prostate; 2003 Apr; 55(1):39-47. PubMed ID: 12640659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In Vitro and In Vivo Characterization of an
    Lütje S; Franssen GM; Herrmann K; Boerman OC; Rijpkema M; Gotthardt M; Heskamp S
    J Nucl Med; 2019 Jul; 60(7):1017-1022. PubMed ID: 30655329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1ng/ml following prostatectomy: How much information can conventional imaging provide?
    Vargas HA; Martin-Malburet AG; Takeda T; Corradi RB; Eastham J; Wibmer A; Sala E; Zelefsky MJ; Weber WA; Hricak H
    Urol Oncol; 2016 Nov; 34(11):482.e5-482.e10. PubMed ID: 27346339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis and pre-clinical evaluation of a new class of high-affinity
    Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. (11)C-choline PET/CT and multiparametric MRI in patients with biochemical relapse of prostate cancer.
    Garcia JR; Romera N; Cozar M; Soler M; Moragas M; Escobar M
    Actas Urol Esp; 2015 May; 39(4):259-63. PubMed ID: 25454265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy.
    Vees H; Buchegger F; Albrecht S; Khan H; Husarik D; Zaidi H; Soloviev D; Hany TF; Miralbell R
    BJU Int; 2007 Jun; 99(6):1415-20. PubMed ID: 17428249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mediastinal lymph node uptake in patients with prostate carcinoma on F18-choline PET/CT.
    Rietbergen DD; van der Hiel B; Vogel W; Stokkel MP
    Nucl Med Commun; 2011 Dec; 32(12):1143-7. PubMed ID: 22045476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic imaging work-up for disease relapse after radical treatment for prostate cancer: how to differentiate local from systemic disease? The urologist point of view.
    Schiavina R; Brunocilla E; Borghesi M; Vagnoni V; Castellucci P; Nanni C; Ceci F; Gacci M; Martorana G; Fanti S
    Rev Esp Med Nucl Imagen Mol; 2013; 32(5):310-3. PubMed ID: 23933383
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.
    Chatalic KL; Veldhoven-Zweistra J; Bolkestein M; Hoeben S; Koning GA; Boerman OC; de Jong M; van Weerden WM
    J Nucl Med; 2015 Jul; 56(7):1094-9. PubMed ID: 25977460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors.
    Leyton JV; Olafsen T; Lepin EJ; Hahm S; Bauer KB; Reiter RE; Wu AM
    Clin Cancer Res; 2008 Nov; 14(22):7488-96. PubMed ID: 19010866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Huber A; Lümmen G; Tscholl R
    Urology; 2000 Apr; 55(4):481-5. PubMed ID: 10736487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [¹¹C]Choline PET/CT predicts survival in hormone-naive prostate cancer patients with biochemical failure after radical prostatectomy.
    Giovacchini G; Incerti E; Mapelli P; Kirienko M; Briganti A; Gandaglia G; Montorsi F; Gianolli L; Picchio M
    Eur J Nucl Med Mol Imaging; 2015 May; 42(6):877-84. PubMed ID: 25697127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sex as a Biologic Variable in Preclinical Imaging Research: Initial Observations with
    Chan SR; Salem K; Jeffery J; Powers GL; Yan Y; Shoghi KI; Mahajan AM; Fowler AM
    J Nucl Med; 2018 May; 59(5):833-838. PubMed ID: 29217733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radioimmunoscintigraphy with a novel monoclonal antiprostate antibody (E4): an experimental study in nude mice.
    Rydh A; Riklund Ahlström K; Widmark A; Johansson L; Nilsson S; Bergh A; Damber JE; Stigbrand T; Hietala SO
    Cancer; 1997 Dec; 80(12 Suppl):2398-403. PubMed ID: 9406689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative PET imaging of experimental tumors with bromine-76-labeled antibodies, fluorine-18-fluorodeoxyglucose and carbon-11-methionine.
    Lövqvist A; Sundin A; Roberto A; Ahlström H; Carlsson J; Lundqvist H
    J Nucl Med; 1997 Jul; 38(7):1029-35. PubMed ID: 9225786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tracking of [18F]FDG-labeled natural killer cells to HER2/neu-positive tumors.
    Meier R; Piert M; Piontek G; Rudelius M; Oostendorp RA; Senekowitsch-Schmidtke R; Henning TD; Wels WS; Uherek C; Rummeny EJ; Daldrup-Link HE
    Nucl Med Biol; 2008 Jul; 35(5):579-88. PubMed ID: 18589302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.